PURPOSE: Distant metastasis is a significant prognostic factor of colon carcinoma. Adjuvant chemotherapy has been shown to decrease its recurrence. However, there are no definitive methods for the diagnosis of hepatic recurrence after potentially curative surgery. The aim of this study was to evaluate the accuracy of mRNA expression profiling using samples obtained from primary tumors to predict hepatic recurrence. METHODS: Patients with stage III colorectal carcinoma without any recurrence for at least 5 years (group A: n = 9) and patients with stage IV carcinoma with hepatic metastasis (group B: n = 10) were included in this study. Tissue samples were collected from the primary tumor and adjacent normal colonic mucosa at the time of surgery in each patient. Total RNA was extracted and the mRNA expression profile was examined using a cDNA macroarray. RESULTS: A hierarchical clustering analysis revealed a dendrogram in which the patients were divided into two clusters. One cluster consisted of seven patients in group A and two in group B. The other consisted of two patients in group A and eight in group B. Therefore, the positive and negative predictive value of hierarchical clustering analysis for hepatic metastasis was 80.0% and 78.8%, respectively. Fifteen genes were revealed to be upregulated and 12 were downregulated in group B. The upregulated genes included CCNA2, TP53, and MDM2, while the downregulated genes included CDH1, GADD45A, and BCL2L2. CONCLUSIONS: mRNA expression profiling by a cDNA array analysis of specimens obtained from primary tumors was found to be useful for distinguishing patients with and without hepatic metastasis. This method is expected to contribute to the identification of patients at high risk for hepatic recurrence, while also helping in the administration of intensive adjuvant chemotherapy for such high risk patients.
PURPOSE: Distant metastasis is a significant prognostic factor of colon carcinoma. Adjuvant chemotherapy has been shown to decrease its recurrence. However, there are no definitive methods for the diagnosis of hepatic recurrence after potentially curative surgery. The aim of this study was to evaluate the accuracy of mRNA expression profiling using samples obtained from primary tumors to predict hepatic recurrence. METHODS:Patients with stage III colorectal carcinoma without any recurrence for at least 5 years (group A: n = 9) and patients with stage IV carcinoma with hepatic metastasis (group B: n = 10) were included in this study. Tissue samples were collected from the primary tumor and adjacent normal colonic mucosa at the time of surgery in each patient. Total RNA was extracted and the mRNA expression profile was examined using a cDNA macroarray. RESULTS: A hierarchical clustering analysis revealed a dendrogram in which the patients were divided into two clusters. One cluster consisted of seven patients in group A and two in group B. The other consisted of two patients in group A and eight in group B. Therefore, the positive and negative predictive value of hierarchical clustering analysis for hepatic metastasis was 80.0% and 78.8%, respectively. Fifteen genes were revealed to be upregulated and 12 were downregulated in group B. The upregulated genes included CCNA2, TP53, and MDM2, while the downregulated genes included CDH1, GADD45A, and BCL2L2. CONCLUSIONS: mRNA expression profiling by a cDNA array analysis of specimens obtained from primary tumors was found to be useful for distinguishing patients with and without hepatic metastasis. This method is expected to contribute to the identification of patients at high risk for hepatic recurrence, while also helping in the administration of intensive adjuvant chemotherapy for such high risk patients.
Authors: O Kitahara; Y Furukawa; T Tanaka; C Kihara; K Ono; R Yanagawa; M E Nita; T Takagi; Y Nakamura; T Tsunoda Journal: Cancer Res Date: 2001-05-01 Impact factor: 12.701
Authors: Y Kitadai; L M Ellis; S L Tucker; G F Greene; C D Bucana; K R Cleary; Y Takahashi; E Tahara; I J Fidler Journal: Am J Pathol Date: 1996-11 Impact factor: 4.307
Authors: C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick Journal: J Clin Oncol Date: 1995-12 Impact factor: 44.544
Authors: K Sumpter; C Harper-Wynne; D Cunningham; A Gillbanks; A R Norman; M Hill Journal: Clin Oncol (R Coll Radiol) Date: 2003-08 Impact factor: 4.126
Authors: David P Ryan; Jeffrey W Clark; Matthew H Kulke; Charles S Fuchs; Craig C Earle; Peter C Enzinger; Keith Stuart; Keith J Catarius; Jennifer Winkelmann; Robert J Mayer Journal: Cancer Invest Date: 2003 Impact factor: 2.176
Authors: Christina M Medina-Ramirez; Sumanta Goswami; Tatiana Smirnova; Daniel Bamira; Benjamin Benson; Neal Ferrick; Jeffrey Segall; Jeffrey W Pollard; Richard N Kitsis Journal: Cancer Res Date: 2011-10-28 Impact factor: 12.701
Authors: Beatriz Carvalho; Anke H Sillars-Hardebol; Cindy Postma; Sandra Mongera; Jochim Terhaar Sive Droste; Askar Obulkasim; Mark van de Wiel; Wim van Criekinge; Bauke Ylstra; Remond J A Fijneman; Gerrit A Meijer Journal: Cell Oncol (Dordr) Date: 2012-01-26 Impact factor: 6.730
Authors: Albert Y Lin; Mei-Sze Chua; Yoon-La Choi; William Yeh; Young H Kim; Raymond Azzi; Gregg A Adams; Kristin Sainani; Matt van de Rijn; Samuel K So; Jonathan R Pollack Journal: PLoS One Date: 2011-02-24 Impact factor: 3.240